Maternal use of opioids during pregnancy and congenital malformations: A systematic review

Pediatrics

Volumn 139, Issue 6, 2017, Pages

  Lind, Jennifer N ^a,b   Interrante, Julia D ^a,c   Ailes, Elizabeth C ^a   Gilboa, Suzanne M ^a   Khan, Sara ^a,d,e   Frey, Meghan T ^a   Dawson, April L ^a   Honein, Margaret A ^a   Dowling, Nicole F ^a   Razzaghi, Hilda ^a,b   Creanga, Andreea A ^f   Broussard, Cheryl S ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b U S PUBLIC HEALTH SERVICE   (United States)

^c OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^d EMORY UNIVERSITY   (United States)

^e Carter Consulting Inc   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; OPIATE DERIVATIVE; OXYCODONE; METHADONE; MORPHINE DERIVATIVE; NARCOTIC ANALGESIC AGENT;

CASE CONTROL STUDY; CLUBFOOT; COHORT ANALYSIS; CONGENITAL MALFORMATION; DESCRIPTIVE RESEARCH; DRUG USE; FEMALE; FOLLOW UP; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; MEDICAL RESEARCH; MOUTH MALFORMATION; PERINATAL DRUG EXPOSURE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STANDARDIZATION; SYSTEMATIC REVIEW; TERATOGENICITY; DRUG INDUCED MALFORMATION; METHODOLOGY; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS;

ABNORMALITIES, DRUG-INDUCED; ANALGESICS, OPIOID; FEMALE; HUMANS; METHADONE; MORPHINE DERIVATIVES; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; RESEARCH DESIGN;

EID: 85020175453     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2016-4131     Document Type: Review

References (96)

1. National Institute on Drug Abuse; US Department of Health and Human Services. Research Report Series: Prescription Drug Abuse. NIH Publication Number 15-4881. Bethesda, MD: National Institute on Drug Abuse, US Department of Health and Human Services; 2014
2. Mack KA, Jones CM, Paulozzi LJ; Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers and other drugs among women-United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2013;62(26):537-542
3. Paulozzi LJ, Mack KA, Hockenberry JM; Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC. Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines-United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(26):563-568
4. Ailes EC, Dawson AL, Lind JN, et al; Centers for Disease Control and Prevention (CDC). Opioid prescription claims among women of reproductive age United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2015;64(2):37-41
5. Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users-United States, 2002-2013. MMWR Morb Mortal Wkly Rep. 2015;64(26):719-725
6. Bateman BT, Hernandez-Diaz S, Rathmell JP, et al. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology. 2014;120(5):1216-1224
7. Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaidenrolled women. Obstet Gynecol. 2014;123(5):997-1002
8. Maeda A, Bateman BT, Clancy CR, Creanga AA, Leffert LR. Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology. 2014;121(6):1158-1165
9. Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129(2). Available at: www.pediatrics.org/cgi/content/full/129/2/e540
10. Center for Substance Abuse Treatment. Substance Abuse Treatment: Addressing the Specific Needs of Women. Treatment Improvement Protocol (TIP) Series, No. 51. HHS Publication No. (SMA) 14-4426. Rockville, MD: Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services; 2009
11. Kelly L, Dooley J, Cromarty H, et al. Narcotic-exposed neonates in a First Nations population in northwestern Ontario: incidence and implications. Can Fam Physician. 2011;57(11):e441-e447
12. Kallen B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6(10):1221-1286
13. Ludlow JP, Evans SF, Hulse G. Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust N Z J Obstet Gynaecol. 2004;44(4):302-306
14. Olofsson M, Buckley W, Andersen GE, Friis-Hansen B. Investigation of 89 children born by drug-dependent mothers. I. Neonatal course. Acta Paediatr Scand. 1983;72(3): 403-406
15. Cleary BJ, Donnelly JM, Strawbridge JD, et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol. 2011;204(2):139.e1-139.e9
16. Saleh Gargari S, Fallahian M, Haghighi L, Hosseinnezhad-Yazdi M, Dashti E, Dolan K. Maternal and neonatal complications of substance abuse in Iranian pregnant women. Acta Med Iran. 2012;50(6):411-416
17. Greig E, Ash A, Douiri A. Maternal and neonatal outcomes following methadone substitution during pregnancy. Arch Gynecol Obstet. 2012;286(4):843-851
18. Little BB, Snell LM, Klein VR, Gilstrap LC III, Knoll KA, Breckenridge JD. Maternal and fetal effects of heroin addiction during pregnancy. J Reprod Med. 1990;35(2):159-162
19. Vucinovic M, Roje D, Vucinovic Z, Capkun V, Bucat M, Banovic I. Maternal and neonatal effects of substance abuse during pregnancy: our tenyear experience. Yonsei Med J. 2008;49(5):705-713
20. Smith MV, Costello D, Yonkers KA. Clinical correlates of prescription opioid analgesic use in pregnancy. Matern Child Health J. 2015;19(3):548-556
21. Ostrea EM, Chavez CJ. Perinatal problems (excluding neonatal withdrawal) in maternal drug addiction: a study of 830 cases. J Pediatr. 1979;94(2):292-295
22. Hulse GK, Milne E, English DR, Holman CD. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction. 1997;92(11):1571-1579
23. Jacobson JL, Jacobson SW, Sokol RJ, Martier SS, Ager JW, Shankaran S. Effects of alcohol use, smoking, and illicit drug use on fetal growth in black infants. J Pediatr. 1994;124(5 pt 1):757-764
24. Brown HL, Britton KA, Mahaffey D, Brizendine E, Hiett AK, Turnquest MA. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol. 1998;179(2):459-463
25. Rosen TS, Johnson HL. Children of methadone-maintained mothers: follow-up to 18 months of age. J Pediatr. 1982;101(2):192-196
26. Kahila H, Saisto T, Kivitie-Kallio S, Haukkamaa M, Halmesmaki E. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand. 2007;86(2):185-190
27. Burns L, Conroy E, Mattick RP. Infant mortality among women on a methadone program during pregnancy. Drug Alcohol Rev. 2010;29(5):551-556
28. Habel L, Kaye K, Lee J. Trends in reporting of maternal drug abuse and infant mortality among drug-exposed infants in New York City. Women Health. 1990;16(2):41-58
29. Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol. 2015;35(8):650-655
30. Baldacchino A, Arbuckle K, Petrie DJ, McCowan C. Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis. BMC Psychiatry. 2014;14:104
31. Baldacchino A, Arbuckle K, Petrie DJ, McCowan C. Erratum: neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis. BMC Psychiatry. 2015;15:134
32. Matthews TJ, MacDorman MF, Thoma ME. Infant mortality statistics from the 2013 period linked birth/infant death data set. Natl Vital Stat Rep. 2015;64(9):1-30
33. Russo CA, Elixhauser A. Hospitalizations for Birth Defects, 2004. Statistical Brief #24. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Healthcare Research and Quality, US Department of Health and Human Services; 2006
34. Broussard CS, Rasmussen SA, Reefhuis J, et al; National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol. 2011;204(4):314.e1-314.e11
35. Yazdy MM, Mitchell AA, Tinker SC, Parker SE, Werler MM. Periconceptional use of opioids and the risk of neural tube defects. Obstet Gynecol. 2013;122(4):838-844
36. Blinick G. Fertility of narcotics addicts and effects of addiction on the offspring. Soc Biol. 1971;18:S34-S39
37. Blinick G, Jerez E, Wallach RC. Methadone maintenance, pregnancy, and progeny. JAMA. 1973;225(5):477-479
38. Blumenthal S, Bergner L, Nelson F. Low birth weight of infants associated with maternal heroin use: New York City, 1966-67 and 1970-71. Health Serv Rep. 1973;88(5):416-418
39. Bracken MB, Holford TR. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol. 1981;58(3):336-344
40. Bracken MB. Drug use in pregnancy and congenital heart disease in offspring. N Engl J Med. 1986;314(17):1120
41. Chasnoff IJ, Hatcher R, Burns WJ. Polydrug-and methadone-addicted newborns: a continuum of impairment? Pediatrics. 1982;70(2):210-213
42. Cleary BJ, Eogan M, O'Connell MP, et al. Methadone and perinatal outcomes: a prospective cohort study. Addiction. 2012;107(8):1482-1492
43. Daud AN, Bergman JE, Bakker MK, et al. P-glycoprotein-mediated drug interactions in pregnancy and changes in the risk of congenital anomalies: a case-reference study. Drug Saf. 2015;38(7):651-659
44. Davis RC, Chappel JN. Pregnancy in the Context of narcotic addiction and methadone maintenance. Proc Natl Conf Methadone Treat. 1973;2:1146-1152
45. Ellwood DA, Sutherland P, Kent C, O'Connor M. Maternal narcotic addiction: pregnancy outcome in patients managed by a specialized drug-dependency antenatal clinic. Aust N Z J Obstet Gynaecol. 1987;27(2):92-98
46. Fajemirokun-Odudeyi O, Sinha C, Tutty S, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol. 2006;126(2):170-175
47. Gillogley KM, Evans AT, Hansen RL, Samuels SJ, Batra KK. The perinatal impact of cocaine, amphetamine, and opiate use detected by universal intrapartum screening. Am J Obstet Gynecol. 1990;163(5 pt 1):1535-1542
48. Green L, Ehrlich S, Finnegan L. The use of tricyclic antidepressants in methadone maintained pregnant women and infant outcome. NIDA Res Monogr. 1988;81:266-272
49. Harper RG, Solish GI, Purow HM, Sang E, Panepinto WC. The effect of a methadone treatment program upon pregnant heroin addicts and their newborn infants. Pediatrics. 1974;54(3):300-305
50. Iosub S, Fuchs M, Bingol N, Stone RK, Gromisch DS, Wasserman E. Incidence of major congenital malformations in offspring of alcoholics and polydrug abusers. Alcohol. 1985;2(3):521-523
51. Jick H, Holmes LB, Hunter JR, Madsen S, Stergachis A. First-trimester drug use and congenital disorders. JAMA. 1981;246(4):343-346
52. Kallen B, Reis M. Use of tramadol in early pregnancy and congenital malformation risk. Reprod Toxicol. 2015;58:246-251
53. Kandall SR, Albin S, Gartner LM, Lee KS, Eidelman A, Lowinson J. The narcoticdependent mother: fetal and neonatal consequences. Early Hum Dev. 1977;1(2):159-169
54. Kivisto K, Tupola S, Kivitie-Kallio S. Prenatally buprenorphine-exposed children: health to 3 years of age. Eur J Pediatr. 2015;174(11):1525-1533
55. Lacroix I, Berrebi A, Garipuy D, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol. 2011;67(10):1053-1059
56. Lam SK, To WK, Duthie SJ, Ma HK. Narcotic addiction in pregnancy with adverse maternal and perinatal outcome. Aust N Z J Obstet Gynaecol. 1992;32(3):216-221
57. Lendoiro E, Gonzalez-Colmenero E, Concheiro-Guisan A, et al. Maternal hair analysis for the detection of illicit drugs, medicines, and alcohol exposure during pregnancy. Ther Drug Monit. 2013;35(3):296-304
58. Lund IO, Skurtveit S, Engeland A, Furu K, Ravndal E, Handal M. Prescription drug use among pregnant women in opioid maintenance treatment. Addiction. 2013;108(2):367-376
59. Maas U, Kattner E, Weingart-Jesse B, Schafer A, Obladen M. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med. 1990;18(2):111-118
60. Metz VE, Comer SD, Pribasnig A, Wuerzl J, Fischer G. Observational study in an outpatient clinic specializing in treating opioid-dependent pregnant women: neonatal abstinence syndrome in infants exposed to methadone-, buprenorphine-and slow-release oral morphine. Heroin Addict Relat Clin Probl. 2015;17(1):5-16
61. Meyer MC, Johnston AM, Crocker AM, Heil SH. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med. 2015;9(2):81-86
62. Miles J, Sugumar K, Macrory F, Sims DG, D'Souza SW. Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants. Child Care Health Dev. 2007;33(2):206-212
63. Naeye RL, Blanc W, Leblanc W, Khatamee MA. Fetal complications of maternal heroin addiction: abnormal growth, infections, and episodes of stress. J Pediatr. 1973;83(6): 1055-1061
64. Newman RG. Results of 120 deliveries of patients in the New York City methadone maintenance treatment program. Proc Natl Conf Methadone Treat. 1973;2:1114-1121
65. Nezvalova-Henriksen K, Spigset O, Nordeng H. Effects of codeine on pregnancy outcome: results from a large population-based cohort study. Eur J Clin Pharmacol. 2011;67(12):1253-1261
66. Norgaard M, Nielsson MS, Heide-Jorgensen U. Birth and neonatal outcomes following opioid use in pregnancy: a Danish population-based study. Subst Abuse. 2015;9(suppl 2):5-11
67. Ramer CM, Lodge A. Neonatal addiction: a two-year study. Part I. Clinical and developmental characteristics of infants of mothers on methadone maintenance. Addict Dis. 1975;2(1-2):227-234
68. Reddy AM, Harper RG, Stern G. Observations on heroin and methadone withdrawal in the newborn. Pediatrics. 1971;48(3):353-358
69. Rothman KJ, Fyler DC, Goldblatt A, Kreidberg MB. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol. 1979;109(4):433-439
70. Saxen I. The association between maternal influenza, drug consumption and oral clefts. Acta Odontol Scand. 1975;33(5):259-267
71. Saxen I. Associations between oral clefts and drugs taken during pregnancy. Int J Epidemiol. 1975;4(1):37-44
72. Shaw GM, Malcoe LH, Swan SH, Cummins SK, Schulman J. Congenital cardiac anomalies relative to selected maternal exposures and conditions during early pregnancy. Eur J Epidemiol. 1992;8(5):757-760
73. Shaw GM, Todoroff K, Velie EM, Lammer EJ. Maternal illness, including fever and medication use as risk factors for neural tube defects. Teratology. 1998;57(1):1-7
74. Stimmel B, Adamsons K. Narcotic dependency in pregnancy. Methadone maintenance compared to use of street drugs. JAMA. 1976;235(11):1121-1124
75. Thaithumyanon P, Limpongsanurak S, Praisuwanna P, Punnahitanon S. Perinatal effects of amphetamine and heroin use during pregnancy on the mother and infant. J Med Assoc Thai. 2005;88(11):1506-1513
76. Thornton L, Clune M, Maguire R, Griffin E, O'Connor J. Narcotic addiction: the expectant mother and her baby. Ir Med J. 1990;83(4):139-142
77. Uebel H, Wright IM, Burns L, et al. Reasons for rehospitalization in children who had neonatal abstinence syndrome. Pediatrics. 2015;136(4). Available at: www.pediatrics.org/cgi/content/full/136/4/e811
78. van Baar AL, Fleury P, Soepatmi S, Ultee CA, Wesselman PJ. Neonatal behavior after drug dependent pregnancy. Arch Dis Child. 1989;64(2):235-240
79. van Gelder MM, Reefhuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N; National Birth Defects Prevention Study. Maternal periconceptional illicit drug use and the risk of congenital malformations. Epidemiology. 2009;20(1):60-66
80. Walhovd KB, Moe V, Slinning K, et al. Volumetric cerebral characteristics of children exposed to opiates and other substances in utero. Neuroimage. 2007;36(4):1331-1344
81. Walhovd KB, Westlye LT, Moe V, et al. White matter characteristics and cognition in prenatally opiate-and polysubstance-exposed children: a diffusion tensor imaging study. AJNR Am J Neuroradiol. 2010;31(5):894-900
82. Welle-Strand GK, Skurtveit S, Jones HE, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. Drug Alcohol Depend. 2013;127(1-3):200-206
83. Werler MM, Yazdy MM, Kasser JR, et al. Medication use in pregnancy in relation to the risk of isolated clubfoot in offspring. Am J Epidemiol. 2014;180(1):86-93
84. White R, Thompson M, Windsor D, Walsh M, Cox D, Charnaud B. Dexamphetamine substituteprescribing in pregnancy: a 10-year retrospective audit. J Subst Use. 2006;11(3):205-216
85. Wilson GS, Desmond MM, Wait RB. Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications. J Pediatr. 1981;98(5):716-722
86. Wilson GS. Clinical studies of infants and children exposed prenatally to heroin. Ann N Y Acad Sci. 1989;562:183-194
87. Wouldes TA, Woodward LJ. Maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol Teratol. 2010;32(3):406-413
88. Zelson C, Rubio E, Wasserman E. Neonatal narcotic addiction: 10 year observation. Pediatrics. 1971;48(2):178-189
89. Zierler S, Rothman KJ. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med. 1985;313(6):347-352
90. Shamliyan TA, Kane RL, Ansari MT, et al. Development quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists. J Clin Epidemiol. 2011;64(6):637-657
91. Paulozzi LJ, Jones CM, Mack KA, Rudd RA; Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011;60(43): 1487-1492
92. Khoury MJ, James LM, Flanders WD, Erickson JD. Interpretation of recurring weak associations obtained from epidemiologic studies of suspected human teratogens. Teratology. 1992;46(1):69-77
93. Jones HE, Heil SH, O'Grady KE, et al. Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples. Am J Drug Alcohol Abuse. 2009;35(5):375-380
94. ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG committee opinion no. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012;119(5):1070-1076
95. Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. Hum Reprod Update. 2011;17(5):589-604
96. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. MMWR Recomm Rep. 2016;65(1):1-49